Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO1993025197 A1
Publication typeApplication
Application numberPCT/US1993/005631
Publication dateDec 23, 1993
Filing dateJun 11, 1993
Priority dateJun 12, 1992
Also published asEP0647133A1, EP0647133A4
Publication numberPCT/1993/5631, PCT/US/1993/005631, PCT/US/1993/05631, PCT/US/93/005631, PCT/US/93/05631, PCT/US1993/005631, PCT/US1993/05631, PCT/US1993005631, PCT/US199305631, PCT/US93/005631, PCT/US93/05631, PCT/US93005631, PCT/US9305631, WO 1993/025197 A1, WO 1993025197 A1, WO 1993025197A1, WO 9325197 A1, WO 9325197A1, WO-A1-1993025197, WO-A1-9325197, WO1993/025197A1, WO1993025197 A1, WO1993025197A1, WO9325197 A1, WO9325197A1
InventorsRon L. Hale, Amy Lu, Dennis Solas, Harold E. Selick, Kevin R. Oldenburg, Alejandro C. Zaffaroni
ApplicantAffymax Technologies N.V.
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Compositions and methods for enhanced drug delivery
WO 1993025197 A1
Description  available in English
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4963367 *Dec 15, 1987Oct 16, 1990Medaphore, Inc.Drug delivery compositions and methods
US5085749 *Jul 24, 1989Feb 4, 1992Massachusetts Institute Of TechnologyDynamically controlled membrane
Non-Patent Citations
Reference
1 *See also references of EP0647133A4
2 *Textbook of Biochemistry (WEST) 1966, 4th edition, see pages 169, 170.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO1996015810A1 *Nov 17, 1995May 30, 1996Michel GeffardConjugues monofonctionnels et/ou polyfonctionnels de la polylysine
WO1996039422A2 *Jun 6, 1996Dec 12, 1996Alza CorporationModification of polypeptide drugs to increase electrotransport flux
WO1996039422A3 *Jun 6, 1996Mar 6, 1997Alza CorpModification of polypeptide drugs to increase electrotransport flux
WO1996039423A2 *Jun 6, 1996Dec 12, 1996Alza CorporationA method for increasing the electrotransport flux of polypeptides
WO1996039423A3 *Jun 6, 1996Jan 30, 1997Alza CorpA method for increasing the electrotransport flux of polypeptides
WO1999059957A1 *May 11, 1999Nov 25, 1999Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
WO2004067546A1 *Jan 28, 2004Aug 12, 2004Helmut KaschTetraalkylammoniumsalze vom kohlensäureestertyp, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2008013860A2 *Jul 26, 2007Jan 31, 2008Xenoport, Inc.Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
WO2008013860A3 *Jul 26, 2007Mar 13, 2008Xuedong DaiAcyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
WO2014181085A1Apr 30, 2014Nov 13, 2014Kenneth Dawson BagshaweTumour therapy
CN104151452B *Jul 16, 2014Feb 1, 2017西北大学聚n‑(2‑羟丙基)甲基丙烯酰胺‑氯尼达明大分子前药及其制备方法
EP0678297A1 *Feb 24, 1995Oct 25, 1995Bristol-Myers Squibb CompanyIontophoretic transdermal delivery of deoxyspergualin compounds
EP0773719A1 *Jul 24, 1995May 21, 1997Emory UniversityCompositions for targeting materials to cells containing androgen receptors
EP0773719A4 *Jul 24, 1995Sep 2, 1998Univ EmoryCompositions for targeting materials to cells containing androgen receptors
EP0796841A1 *Mar 14, 1997Sep 24, 1997Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Bis alkanoyl esters of carnitine having bactericidal, fungicidal and antiprotozoal activity
EP0814789B2Mar 1, 1996Jan 9, 2008R.P. Scherer Technologies, Inc.Pharmaceutical compositions comprising monoamine oxidase b inhibitors
EP1484313A1 *May 11, 1999Dec 8, 2004Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
EP2670763A1 *Feb 1, 2012Dec 11, 2013Suzhou Neupharma Co., LtdCertain chemical entities, compositions, and methods
EP2670763A4 *Feb 1, 2012Nov 12, 2014Suzhou Neupharma Co LtdCertain chemical entities, compositions, and methods
US5721226 *Jun 7, 1995Feb 24, 1998Magainin Pharmaceuticals Inc.Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
US5733899 *Sep 13, 1994Mar 31, 1998Magainin Pharmaceuticals Inc.Method for treating infection using steroid based pharmaceutical compositions
US5747453 *Jun 6, 1995May 5, 1998Alza CorporationMethod for increasing the electrotransport flux of polypeptides
US5763430 *Jun 7, 1995Jun 9, 1998Magainin Pharmaceuticals Inc.Method of treating a viral infection by administering a steroid compound
US5792635 *Jun 7, 1995Aug 11, 1998Magainin Pharmaceuticals, Inc.Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US5795885 *Jun 7, 1995Aug 18, 1998Magainin Pharmaceuticals Inc.Method of inhibiting profileration of cells by administering an aminosterol compound
US5840740 *Jun 7, 1995Nov 24, 1998Magainin Pharmaceuticals Inc.Aminosterol compounds and a method of treating infection using the aminosterol compounds
US5840936 *Jun 7, 1995Nov 24, 1998Magainin Pharmaceuticals Inc.Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US5847172 *Jun 7, 1995Dec 8, 1998Magainin Pharmaceuticals Inc.Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5856535 *Dec 18, 1996Jan 5, 1999Magainin Pharmaceuticals, Inc.Aminosterol ester compounds
US5874597 *Jun 7, 1995Feb 23, 1999Magainin Pharmaceuticals, Inc.Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994336 *Jun 7, 1995Nov 30, 1999Magainin Pharmaceuticals Inc.Method of inhibiting proliferation of cells by administering an aminosterol compound
US6114388 *Nov 17, 1995Sep 5, 2000Geffard; MichelMonofunctional and/or polyfunctional polylysine conjuages
US6143738 *May 16, 1997Nov 7, 2000Magainin Pharmaceuticals, Inc.Therapeutic uses for an aminosterol compound
US6147060 *Apr 25, 1997Nov 14, 2000Magainin PharmaceuticalsTreatment of carcinomas using squalamine in combination with other anti-cancer agents
US6262283Dec 5, 1997Jul 17, 2001Magainin Pharmaceuticals Inc.Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US6313092Jan 15, 1998Nov 6, 2001Alza CorporationMethod for increasing the electrotransport flux of polypeptides
US6333189Jun 6, 1996Dec 25, 2001Alza CorporationMethod of making an electrotransport device
US6468981Jul 29, 1994Oct 22, 2002Emory UniversityCompositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US6596712Mar 12, 2001Jul 22, 2003Genaera CorporationTreatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6610841Dec 18, 1997Aug 26, 2003Gilead Sciences, Inc.Nucleotide-based prodrugs
US6610866Apr 12, 2001Aug 26, 2003Magainin Pharmaceuticals, Inc.Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
US6818787Jun 11, 2002Nov 16, 2004Xenoport, Inc.Prodrugs of GABA analogs, compositions and uses thereof
US6833140Jun 11, 2002Dec 21, 2004Xenoport, Inc.Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US6933383Oct 11, 2002Aug 23, 2005Genaera CorporationRegioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
US6956060Nov 27, 2002Oct 18, 2005Teva Pharmaceutical Industries, Ltd.Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US6972341Jun 10, 2003Dec 6, 2005Xeno Port, Inc.Prodrugs of GABA analogs, compositions and uses thereof
US7186855Dec 6, 2002Mar 6, 2007Xenoport, Inc.Prodrugs of GABA analogs, compositions and uses thereof
US7324846Dec 10, 2001Jan 29, 2008Alza Corp.Method of enchancing electrontransport polypeptide flux by amino acid substitution with histidine
US7531572Jul 26, 2007May 12, 2009Xenoport, Inc.Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US7728157Mar 21, 2005Jun 1, 2010Ohr Pharmaceutical Inc.Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
US7790708May 22, 2006Sep 7, 2010Xenoport, Inc.Prodrugs of GABA analogs, compositions and uses thereof
US7799829Apr 1, 2009Sep 21, 2010Xenoport, Inc.Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US8048917Apr 6, 2005Nov 1, 2011Xenoport, Inc.Prodrugs of GABA analogs, compositions and uses thereof
US8071737Nov 23, 2009Dec 6, 2011Glead Sciences, Inc.Nucleic acid ligand complexes
US8168623Jul 1, 2010May 1, 2012Xenoport, Inc.Prodrugs of GABA analogs, compositions and uses thereof
US8349866Jul 31, 2009Jan 8, 2013Chongxi YuHigh penetration prodrug compositions of 1H-imidazo[4,5-C]quinolin-4-amines and 1H-imidazo[4,5-C]quinolin-4-amine-related compounds
US8431576Jun 24, 2010Apr 30, 2013Alkermes Pharma Ireland LimitedHeterocyclic compounds for the treatment of neurological and psychological disorders
US8592427Jun 24, 2011Nov 26, 2013Alkermes Pharma Ireland LimitedProdrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8686009Jun 24, 2010Apr 1, 2014Alkermes Pharma Ireland LimitedProdrugs of NH-acidic compounds
US8795725Nov 3, 2005Aug 5, 2014Xenoport, Inc.GABA analog prodrug sustained release oral dosage forms
US8906412Jun 19, 2014Dec 9, 2014Xenoport, Inc.GABA analog prodrug sustained release oral dosage forms
US8969337Dec 14, 2012Mar 3, 2015Alkermes Pharma Ireland LimitedProdrugs of secondary amine compounds
US8993550Nov 9, 2012Mar 31, 2015Suzhou Neupharma Co., Ltd.Certain chemical entities, compositions, and methods
US9018197Aug 26, 2011Apr 28, 2015Suzhou Neupharma Co. Ltd.Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
US9034867Mar 19, 2012May 19, 2015Alkermes Pharma Ireland LimitedPharmaceutical compositions comprising sorbitan esters
US9193685Sep 19, 2013Nov 24, 2015Alkermes Pharma Ireland LimitedPharmaceutical compositions having improved storage stability
US9238616Jul 6, 2015Jan 19, 2016Xenoport, Inc.Prodrugs of gaba analogs, compositions and uses thereof
US9340570Apr 29, 2013May 17, 2016Neupharma, Inc.Certain chemical entities, compositions, and methods
US9351976May 18, 2015May 31, 2016Alkermes Pharma Ireland LimitedPharmaceutical compositions comprising sorbitan esters
US9371284Jun 4, 2007Jun 21, 2016Techfields Pharma Co., Ltd.Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses
US9399659Feb 18, 2015Jul 26, 2016Suzhou Neupharma Co., LtdCertain chemical entities, compositions, and methods
US9452131Mar 19, 2015Sep 27, 2016Alkermes Pharma Ireland LimitedAripiprazole formulations having increased injection speeds
US9493503Feb 1, 2012Nov 15, 2016Neupharma, Inc.Certain chemical entities, compositions, and methods
US9526726May 25, 2016Dec 27, 2016Alkermes Pharma Ireland LimitedAripiprazole formulations having increased injection speeds
US9567329Dec 31, 2012Feb 14, 2017Techfields Pharma Co., Ltd.High penetration prodrug compositions of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds and uses thereof
US9676813Apr 29, 2013Jun 13, 2017Neupharma, Inc.Certain steroids and methods for using the same in the treatment of cancer
US9814735Jun 20, 2016Nov 14, 2017Suzhou Neupharma Co., LtdCertain chemical entities, compositions, and methods
USRE40861Nov 30, 2006Jul 21, 2009Sigma-Tau Industrie Farmaceutiche Reunite S.p.A.Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
USRE41226Dec 1, 2006Apr 13, 2010Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
Classifications
International ClassificationA61K9/00, A61K47/48
Cooperative ClassificationA61K47/6957, A61K47/541, B82Y5/00, A61K31/568, A61K9/0009
European ClassificationB82Y5/00, A61K9/00L8, A61K47/48W26, A61K47/48H4A, A61K31/568
Legal Events
DateCodeEventDescription
Dec 23, 1993AKDesignated states
Kind code of ref document: A1
Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US
Dec 23, 1993ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
Apr 6, 1994121Ep: the epo has been informed by wipo that ep was designated in this application
May 26, 1994DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
Jan 12, 1995WWEWipo information: entry into national phase
Ref document number: 1993915319
Country of ref document: EP
Mar 30, 1995REGReference to national code
Ref country code: DE
Ref legal event code: 8642
Apr 12, 1995WWPWipo information: published in national office
Ref document number: 1993915319
Country of ref document: EP
Feb 12, 1996NENPNon-entry into the national phase in:
Ref country code: CA
Jun 3, 1998WWWWipo information: withdrawn in national office
Ref document number: 1993915319
Country of ref document: EP